BioSpace News Archive

Through Triple Play, Boys & Girls Clubs of America and Anthem Blue Cross and Blue Shield Foundation are delivering education and programming that promotes the importance of physical activity and proper nutrition, and enables youth to build the skills needed to overcome environmental factors that can negatively impact health and wellness.

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the achievement of major milestones in its clinical trial programs.

Barclays announces the appointment of David Parrot as Managing Director and Head of Barclays’ US West Coast Biotech Banking franchise.

Immix Biopharma, Inc announced today positive interim results from its ongoing phase 1b/2a study testing IMX-110 in advanced solid tumors. Immix observed Stable Disease at cohort (dose-level) 2 in a middle-aged male with stage IV colorectal cancer that was refractory to radiation therapy, chemotherapy and immunotherapy.

Economic growth in the United States will continue in 2019, say the nation’s purchasing and supply management executives in the December 2018 Semiannual Economic Forecast.

Geneious Biologics, an enterprise software solution for companies engaged in screening of antibodies and antibody-like molecules, has been selected by FairJourney Biologics, a leading contract research organization (CRO), to support the company’s growth as it incorporates increasingly large Sanger data sets and next-generation sequencing (NGS) into its discovery programs.

Hosted by UBM Sinoexpo

Bristol-Myers Squibb Company and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers.

Alnylam Pharmaceuticals, Inc. announced today that it has resolved all litigation worldwide with Silence Therapeutics.

Over 91,000 doses of rimegepant 75mg administered across 1,780 patients with migraine